Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Akshara S. Raghavendra"'
Autor:
Smruthi Vijayaraghavan, Cansu Karakas, Iman Doostan, Xian Chen, Tuyen Bui, Min Yi, Akshara S. Raghavendra, Yang Zhao, Sami I. Bashour, Nuhad K. Ibrahim, Meghan Karuturi, Jing Wang, Jeffrey D. Winkler, Ravi K. Amaravadi, Kelly K. Hunt, Debu Tripathy, Khandan Keyomarsi
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-17 (2017)
CDK4/6-Cyclin D pathway is often deregulated in cancer; therefore specific inhibitors have been developed. Here the authors show that treatment with CDK4/6 inhibitors activate autophagy in breast cancer cells; thus, combination of such inhibitors wit
Externí odkaz:
https://doaj.org/article/29244e97db3b4325b02bb495622f99c7
Autor:
Sheheryar Kabraji, Jing Ni, Sarah Sammons, Tianyu Li, Amanda E.D. Van Swearingen, Yanzhi Wang, Alyssa Pereslete, Liangge Hsu, Pamela J. DiPiro, Chris Lascola, Heather Moore, Melissa Hughes, Akshara S. Raghavendra, Maria Gule-Monroe, Rashmi K. Murthy, Eric P. Winer, Carey K. Anders, Jean J. Zhao, Nancy U. Lin
Publikováno v:
Clin Cancer Res
Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd732bc462df40bf3795d7807bf20c2f
https://doi.org/10.1158/1078-0432.ccr-22-1138
https://doi.org/10.1158/1078-0432.ccr-22-1138
Autor:
Nancy U. Lin, Jean J. Zhao, Carey K. Anders, Eric P. Winer, Rashmi K. Murthy, Maria Gule-Monroe, Akshara S. Raghavendra, Melissa Hughes, Heather Moore, Chris Lascola, Pamela J. DiPiro, Liangge Hsu, Alyssa Pereslete, Yanzhi Wang, Amanda E.D. Van Swearingen, Tianyu Li, Sarah Sammons, Jing Ni, Sheheryar Kabraji
Purpose:Brain metastases can occur in up to 50% of patients with metastatic HER2-positive breast cancer. Because patients with active brain metastases were excluded from previous pivotal clinical trials, the central nervous system (CNS) activity of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071e468ffb7bb336ccd6cd64f6d1d7b1
https://doi.org/10.1158/1078-0432.c.6532872.v1
https://doi.org/10.1158/1078-0432.c.6532872.v1
Autor:
Nancy U. Lin, Jean J. Zhao, Carey K. Anders, Eric P. Winer, Rashmi K. Murthy, Maria Gule-Monroe, Akshara S. Raghavendra, Melissa Hughes, Heather Moore, Chris Lascola, Pamela J. DiPiro, Liangge Hsu, Alyssa Pereslete, Yanzhi Wang, Amanda E.D. Van Swearingen, Tianyu Li, Sarah Sammons, Jing Ni, Sheheryar Kabraji
Figures S1 and S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79cd1c4aae60dc5fd89e823c842f4a0a
https://doi.org/10.1158/1078-0432.22489053.v1
https://doi.org/10.1158/1078-0432.22489053.v1
Autor:
Khandan Keyomarsi, Debu Tripathy, Kelly K. Hunt, David J. Tweardy, Aysegul Sahin, Stephanie S. Watowich, Meghan Sri Karuturi, Nuhad K. Ibrahim, Akshara S. Raghavendra, T. Kris Eckols, Xian Chen, Jason P.W. Carey, Min Yi, Jing Wang, Xiayu Rao, Bin Liu, Min Jin Ha, Mehrnoosh Kohansal, Tuyen Bui, Merih Guray Durak, Smruthi Vijayaraghavan, Nicole M. Kettner
Supplementary Data from Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1719d34a1d0e6d9e8f4e1ddbf5167f1f
https://doi.org/10.1158/1078-0432.22475867.v1
https://doi.org/10.1158/1078-0432.22475867.v1
Autor:
Khandan Keyomarsi, Debu Tripathy, Kelly K. Hunt, David J. Tweardy, Aysegul Sahin, Stephanie S. Watowich, Meghan Sri Karuturi, Nuhad K. Ibrahim, Akshara S. Raghavendra, T. Kris Eckols, Xian Chen, Jason P.W. Carey, Min Yi, Jing Wang, Xiayu Rao, Bin Liu, Min Jin Ha, Mehrnoosh Kohansal, Tuyen Bui, Merih Guray Durak, Smruthi Vijayaraghavan, Nicole M. Kettner
Purpose:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor–positive, HER2-negative breast cancer. Although this treatment doubles time to progression compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::866981ce359d67f9e3d05d0e9295d988
https://doi.org/10.1158/1078-0432.c.6529199
https://doi.org/10.1158/1078-0432.c.6529199
Publikováno v:
Journal of the Endocrine Society. 6:A877-A878
Background Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) contributes to nearly 70% of breast cancer-related deaths. Liver metastasis is the third most common site and has been found to carry a poor prognosis. One contributing factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0868906fe161be13c4917877170f5871
https://doi.org/10.1210/jendso/bvac150.1816
https://doi.org/10.1210/jendso/bvac150.1816
Autor:
Sheheryar Kabraji, Jing Ni, Sarah Sammons, Amanda ED Van Swearingen, Yanzhi Wang, Alyssa M Pereslete, Liangge Hsu, Chris Lascola, Heather Moore, Melissa Hughes, Akshara S Raghavendra, Maria Gule-Monroe, Rashmi K Murthy, Eric P Winer, Carey K Anders, Jean J Zhao, Nancy U Lin
Publikováno v:
Cancer Research. 82:PD4-05
Purpose: Up to half of patients (pts) with HER2+ metastatic breast cancer (MBC) will develop BCBM. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) with demonstrated efficacy in previously treated pts with HER2+ MBC. However, few pt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::229e007abb9005a5fbb80dce140e9780
https://doi.org/10.1158/1538-7445.sabcs21-pd4-05
https://doi.org/10.1158/1538-7445.sabcs21-pd4-05
Autor:
Juliana Navarro-Yepes, Nicole M. Kettner, Tuyen Bui, Akshara S. Raghavendra, Xiayu Rao, Jing Wang, Aysegul Sahin, Senthil Damodaran, Debasish Tripathy, Kelly K. Hunt, Khandan Keyomarsi
Publikováno v:
Cancer Research. 82:1798-1798
Background: CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) delay progression and improve survival in patients with hormone receptor positive (HR+), HER2 negative metastatic breast cancer (MBC). However, most patients develop resistance to CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6042292a04de8a493e32c60e0bd461ce
https://doi.org/10.1158/1538-7445.am2022-1798
https://doi.org/10.1158/1538-7445.am2022-1798
Autor:
Ayca N. Mogol, Christine Chien, Qianying Zuo, Akshara S. Raghavendra, Debu Tripathy, Yosef Landesman, Zeynep Madak Erdogan
Publikováno v:
Cancer Research. 82:2698-2698
Approximately 70% of human breast cancers express estrogen receptor alpha (ERα), providing a potential for targeted endocrine therapy for patients. Unfortunately, 30-40% of ER+ patients still experience recurrence and metastasis, with a 5-year relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fab1efcd346bc5d77d4254c9fe5811ea
https://doi.org/10.1158/1538-7445.am2022-2698
https://doi.org/10.1158/1538-7445.am2022-2698